BRISTOL MYERS SQUIBB CO files DEFA14A

This supplemental proxy filing from Bristol-Myers Squibb Company provides an update on the company's performance and governance practices, including its 2025 financial results and the board's recommendations for the upcoming 2026 Annual Meeting. Shareholders will vote on the election of directors, an advisory vote on executive compensation, the approval of a new stock award plan, and the ratification of the independent auditor, as well as a shareholder proposal regarding board leadership.